title: Percutaneous radiofrequency ablation for unresectable large hepatic tumours during hepatic blood flow occlusion in four patients.
abstract: OBJECTIVE
  To evaluate percutaneous radiofrequency (RF) ablation therapy for unresectable large hepatic tumours combined with regional interruption of hepatic blood flow, and to assess the safety and efficacy of this procedure.
  
  
  METHODS
  Four patients with hepatic tumours were enrolled in this study. Patients were treated by a single session of RF ablation during occlusion of both hepatic artery and hepatic vein. Tumour size ranged from 45-57 mm (mean 50.2 mm). Initial therapeutic efficacy was evaluated with helical computed tomography (CT) performed within 9 days after the treatment. CT or magnetic resonance imaging (MRI) was performed every 2-3 months thereafter.
  
  
  RESULTS
  The largest axis of coagulated lesions after the ablation was 50-60 mm (mean 56.5 mm) in diameter. The ablation therapy was considered complete in three patients; after a mean follow-up of 12.7 months, CT and MRI revealed complete destruction of their tumours. One patient required further treatment. No severe complications occurred.
  
  
  CONCLUSIONS
  Although further studies are needed, in this limited clinical trial a local ablation area exceeding 50 mm in diameter was achieved safely.
authors.affiliation: Department of Radiology, Teine Keijinkai Hospital, Sapporo, Japan. nm-00@fg7.so-net.ne.jp
authors.forename: N
authors.initials: N
authors.lastname: Miyamoto
authors.forename: K
authors.initials: K
authors.lastname: Tsuji
authors.forename: Y
authors.initials: Y
authors.lastname: Sakurai
authors.forename: H
authors.initials: H
authors.lastname: Nishimori
authors.forename: J-H
authors.initials: JH
authors.lastname: Kang
authors.forename: S
authors.initials: S
authors.lastname: Mitsui
authors.forename: H
authors.initials: H
authors.lastname: Maguchi
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D014057:Tomography, X-Ray Computed